Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY

Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven M. Larson, Howard I. Scher and Hebert Alberto Vargas
Journal of Nuclear Medicine January 2021, jnumed.120.256602; DOI: https://doi.org/10.2967/jnumed.120.256602
Andreas G. Wibmer
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andreas G. Wibmer
Michael J. Morris
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mithat Gonen
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junting Zheng
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hedvig Hricak
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Larson
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard I. Scher
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hebert Alberto Vargas
Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.120.256602
DOI 
https://doi.org/10.2967/jnumed.120.256602
PubMed 
33419944

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online January 8, 2021.

Article Versions

  • You are currently viewing a previous version of this article (January 8, 2021 - 13:20).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Andreas G. Wibmer,
  2. Michael J. Morris,
  3. Mithat Gonen,
  4. Junting Zheng,
  5. Hedvig Hricak,
  6. Steven M. Larson,
  7. Howard I. Scher and
  8. Hebert Alberto Vargas
  1. Memorial Sloan Kettering Cancer Center, United States
  1. For correspondence or reprints contact: Andreas G. Wibmer, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States. E-mail: wibmera@mskcc.org

Statistics from Altmetric.com

Cited By...

  • 21 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Salvage therapy for prostate cancer after radical prostatectomy
    Nicholas G. Zaorsky, Jeremie Calais, Stefano Fanti, Derya Tilki, Tanya Dorff, Daniel E. Spratt, Amar U. Kishan
    Nature Reviews Urology 2021 18 11
  • The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients
    Matteo Bauckneht, Francesco Bertagna, Maria Isabella Donegani, Rexhep Durmo, Alberto Miceli, Vincenzo De Biasi, Riccardo Laudicella, Giuseppe Fornarini, Alfredo Berruti, Sergio Baldari, Annibale Versari, Raffaele Giubbini, Gianmario Sambuceti, Silvia Morbelli, Domenico Albano
    Prostate Cancer and Prostatic Diseases 2021 24 4
  • The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
    Goutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, Bastien Nguyen, Konrad H. Stopsack, Christoph Kreitzer, Sai Harisha Rajanala, Romina Ghale, Ying Z. Mazzu, Naga Vara Kishore Pillarsetty, Gwo-Shu Mary Lee, Howard I. Scher, Michael J. Morris, Tiffany Traina, Pedram Razavi, Wassim Abida, Jeremy C. Durack, Stephen B. Solomon, Matthew G. Vander Heiden, Lorelei A. Mucci, Andreas G. Wibmer, Nikolaus Schultz, Philip W. Kantoff
    Clinical Cancer Research 2022 28 16
  • Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT
    Fadi Khreish, Kalle Ribbat, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier, Johannes Linxweiler, Mathias Schreckenberger, Samer Ezziddin, Florian Rosar
    Cancers 2021 13 16
  • Freely Available, Fully Automated AI-Based Analysis of Primary Tumour and Metastases of Prostate Cancer in Whole-Body [18F]-PSMA-1007 PET-CT
    Elin Trägårdh, Olof Enqvist, Johannes Ulén, Jonas Jögi, Ulrika Bitzén, Fredrik Hedeer, Kristian Valind, Sabine Garpered, Erland Hvittfeldt, Pablo Borrelli, Lars Edenbrandt
    Diagnostics 2022 12 9
  • A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
    Ana Ruiz-Garcia, Paul Baverel, Dean Bottino, Michael Dolton, Yan Feng, Ignacio González-García, Jaeyeon Kim, Seth Robey, Indrajeet Singh, David Turner, Shu-Pei Wu, Donghua Yin, Di Zhou, Hao Zhu, Peter Bonate
    Journal of Pharmacokinetics and Pharmacodynamics 2023 50 3
  • SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases
    Nazanin Zamani-Siahkali, Seyed Ali Mirshahvalad, Abolfazl Farbod, Ghasemali Divband, Christian Pirich, Patrick Veit-Haibach, Gary Cook, Mohsen Beheshti
    Seminars in Nuclear Medicine 2024 54 3
  • Role of volumetric parameters obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane therapy
    Yunus Güzel, Halil Kömek, Canan Can, İhsan Kaplan, Nadiye Akdeniz, Ferat Kepenek, Cihan Gündoğan
    Annals of Nuclear Medicine 2023 37 9
  • Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence
    Bingsheng Huang, Qinqin Yang, Xiao Li, Yuxuan Wu, Zhantao Liu, Zhaohong Pan, Shaonan Zhong, Shaoli Song, Changjing Zuo
    European Journal of Nuclear Medicine and Molecular Imaging 2024 51 4
  • Starving lethal prostate cancer by targeting heat shock proteins and glycolytic enzymes
    Stephen R. Plymate, Cynthia Sprenger, Michael C. Haffner
    Cell Reports Medicine 2022 3 2

Article usage

Article usage: January 2021 to April 2025

AbstractFullPdf
Jan 20211741053
Feb 2021340017
Mar 2021218017
Apr 202112703
May 202116906
Jun 202113205
Jul 20213742357
Aug 2021116365109
Sep 20216071442
Oct 20215221928
Nov 2021344944
Dec 2021348722
Jan 20224751619
Feb 20226333622
Mar 20225130850
Apr 20224119626
May 20222420134
Jun 20223630323
Jul 20221535817
Aug 20221829332
Sep 20222233124
Oct 20221418828
Nov 2022158019
Dec 20222239117
Jan 20232538317
Feb 20231135218
Mar 20231037824
Apr 20231427627
May 20231116727
Jun 20231018416
Jul 2023520117
Aug 20231632018
Sep 2023926211
Oct 20231319019
Nov 20231725317
Dec 2023175512
Jan 20241313824
Feb 20241619617
Mar 20241012622
Apr 2024717535
May 2024112823
Jun 2024173927
Jul 2024109220
Aug 20241610528
Sep 202473627
Oct 202452314
Nov 202442614
Dec 202463519
Jan 202532617
Feb 2025137518
Mar 202576622
Apr 202565430
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven M. Larson, Howard I. Scher, Hebert Alberto Vargas
Journal of Nuclear Medicine Jan 2021, jnumed.120.256602; DOI: 10.2967/jnumed.120.256602

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY
Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven M. Larson, Howard I. Scher, Hebert Alberto Vargas
Journal of Nuclear Medicine Jan 2021, jnumed.120.256602; DOI: 10.2967/jnumed.120.256602
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • The added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer
Show more Clinical Investigations (Human)

Clinical (Oncology: GU)

  • Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
  • A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
  • Detection of Additional Primary Neoplasms on 18F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer
Show more Clinical (Oncology: GU)

Similar Articles

Keywords

  • Genitourinary
  • Molecular imaging
  • Oncology: GU
  • PET/CT
  • 18F-fluoro-desoxy-glucose positron-emission tomography computed tomography
  • abiraterone; enzalutamide
  • metastatic prostate cancer
  • overall survival
  • whole-body tumor burden
SNMMI

© 2025 SNMMI

Powered by HighWire